Cefiderocol
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics
Conditions
Pharmacokinetics
Trial Timeline
Jul 25, 2022 → Nov 20, 2024
NCT ID
NCT05373615About Cefiderocol
Cefiderocol is a phase 1 stage product being developed by Shionogi for Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT05373615. Target conditions include Pharmacokinetics.
What happened to similar drugs?
5 of 5 similar drugs in Pharmacokinetics were approved
Approved (5) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03780140 | Pre-clinical | Completed |
| NCT07465432 | Approved | Recruiting |
| NCT05789199 | Pre-clinical | Completed |
| NCT05373615 | Phase 1 | Completed |
| NCT05314764 | Approved | Completed |
| NCT04995835 | Phase 1 | Completed |
| NCT03869437 | Phase 2 | Completed |
Competing Products
20 competing products in Pharmacokinetics